The manner in which pre-menstrual and menopausal indications for soy and red clover isoflavones that recently won approval from the European Patent Office can be translated into marketing messages, is being debated among soy players.
Preliminary research in the US finds that soy isoflavones, found in
soy infant formula, do not disrupt infant development, despite
concerns from some scientists that the isoflavones could act like
female hormones in infants.